Notably, bumetanide and VEGF inhibitors show promise for traumatic brain injury (TBI) (Michinaga and Koyama, 2021), while monoamine oxidase B (MAO-B) inhibitors and A2A receptor antagonists hold potential for AD (Sanmarco et al., 2021; Nam et al., 2023). Here, VEGFA is linked to brain injury.